Novartis Venture Fund and Venture Investors, a venture capital (VC) firm investing in university technology transfer start-ups throughout the Midwest of America, co-led the $22m B round for Akebia Therapeutics.
Akebia Therapeutics, a US-based pharmaceutical discovery and development company focused on blood disorders, has raised $22m in its series B round from a consortium co-led by Switzerland-based drugs company Novartis’ corporate venturing unit.
Novartis Venture Fund and Venture Investors, a venture capital (VC) firm investing in university technology transfer start-ups throughout the Midwest of America, co-led the B round. VC firms Triathlon Medical Ventures, Kearny Venture Partners, Athenian Venture Partners and Sigvion Capital also reinvested in Akebia and were joined…
